Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Lexicon Pharmaceuticals Q3 2026 Results: Net Loss of $14M, Loss Widens

Lexicon Pharmaceuticals reported a net loss of $46.8 million for the nine months ended September 30, 2026, compared to $34.8 million in the prior year period. The company strengthened its balance sheet through common and preferred stock issuances, ending the period with $183.2 million in cash and short-term investments.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue11.214.2
Net income-14.0-12.8
EPS (diluted, $ a share)$-0.03$-0.04

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-20.7%
Operating margin-128.8%
Source

10-Q filed with the SEC, NASDAQ: LXRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Lexicon Pharmaceuticals, Inc.: key numbers

Share price
$1.75Close, Nov 16
Market cap
$779M
Shares outstanding
445.23MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Lexicon Pharmaceuticals, Inc.

All →
8:14 AM ET Form 4
Insider Buying

Lexicon Pharmaceuticals CEO Michael Exton Buys $50K of Stock

Michael Exton, CEO, bought 30,064 shares of Lexicon Pharmaceuticals, Inc. at $1.66 a share, worth $50K in total on Nov 6, 2026. Shares held after the trade: 328,496 (+10.1%).

Value
$50K
Shares
30,064
Price
$1.66
Role
CEO
Holding change
+10.1%
Trade date
Nov 6, 2026
7:08 AM ET 8-K
Financial Results

Lexicon Pharmaceuticals Financial Results

Lexicon Pharmaceuticals reported Q3 2026 financial results and provided clinical updates, including the completion of enrollment for its Phase 3 SONATA-HCM study. The company also confirmed it has achieved the safety data requirements for its ZYNQUISTA NDA resubmission in type 1 diabetes.

Term
3 months

“This quarter brought Lexicon into sharper focus as a cardiometabolic company and has positioned us to approach 2027 with strong momentum and multiple near-term potential catalysts and paths to value creation.”

Mike Exton, Ph.D., Lexicon’s chief executive officer and director

“As we prepare for several important milestones across our portfolio, we remain focused on investing prudently to support execution and position the Company for long-term success.”

Scott Coiante, Lexicon’s chief financial officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.